In 129 of 141 randomised patients with newly diagnosed MGMT-methylated glioblastoma, lomustine-temozolomide plus radiotherapy vs temozolomide chemoradiotherapy: median OS 48·1 vs 31·4 months (HR 0·60, 95% CI 0·35–1·03; p=0·0492). Grade ≥3 events 59% vs 51%.
RCTn = 141
Herrlinger et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial